Abstract: Background: Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MiRNA deregulation was extensively studied in PTCs and FTCs; however, very limited information is available for FVPTC. The aim of this study was to assess miRNA expression in FVPTC with the most comprehensive miRNA array panel and correlate it with the clinicopathological data. Methods: Fortyfour papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and 8 normal thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray Assays on ABI 7900 (Life Technologies). In addition, an independent set of 61 tumor and normal samples was studied for expression of novel miRNA markers detected in this study. Results: Overall, the miRNA expression profile demonstrated similar trends in expression between FVPTC and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than 5 (up/down) including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the levels of miRNA expression were different between these tumor types and some miRNAs were uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large independent set of follicular cell derived neoplasms and benign nodules and demonstrated specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated with an adverse outcome in FVPTC patients by a Kaplan Meier (p<0.05) and multivariate Cox regression analysis (p<0.05). Conclusions: Despite high similarity in miRNA expression between FVPTC and classic PTC, several miRNAs were uniquely expressed in each tumor type supporting their histopathologic differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel marker of papillary thyroid carcinoma and miR-181a-2-3p and miR-99b-3p can predict relapse free survival in patients with FVPTC potentially providing important diagnostic and predictive value. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
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Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. (doi: 10.1089/thy.2012.0632) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Universitä tsSpital Zürich 47
Institut 
Thyroid
with an adverse outcome in FVPTC patients by a Kaplan Meier (p<0.05) and multivariate Cox 96 regression analysis (p<0.05). 97
Conclusions: Despite high similarity in miRNA expression between FVPTC and classic PTC, 98 several miRNAs were uniquely expressed in each tumor type supporting their histopathologic 99 differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel 100 marker of papillary thyroid carcinoma and miR-181a-2-3p and miR-99b-3p can predict relapse-101 free survival in patients with FVPTC thus potentially providing important diagnostic and 102 predictive value. 103 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. pattern and complete lack of well-formed papillae (2). Moreover, the metastatic pattern of these 115 tumors often resembles classic PTC with cervical lymph node metastasis but, some cases may 116 demonstrate distant hematologic metastases, a finding more common in FTC (4). 117
INTRODUCTION

118
At the molecular level, FVPTCs also appear as an entity located between PTC and FTC. It 119 frequently harbors RAS mutations and the PAX8/PPARγ rearrangement can also be detected; both 120 events are common in follicular tumors and are rare in classic PTC (5). On the other hand, it may 121 have BRAF gene mutations -but, in contrast to the usual BRAF V600E found in classic PTC, 122 FVPTC have a distinct BRAF K601E mutation. BRAF K601E is very rare in FTC and was only 123 described in one case in previous publications (6, 7). In addition, the overall gene expression 124 profile in FVPTC is distinct from classic PTC, underlining these differences (8, 9 The goal of this study was to examine miRNA expression in a large series of FVPTC using the 136 most comprehensive miRNA profile available and correlate it with the clinicopathological data. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. hematoxylin and eosin-stained slide using an Olympus SZ61 stereomicroscope (Olympus, 168 Hamburg, Germany). RNA quality and quantity was assessed with a spectrophotometer 169 (NanoDrop 1000, Thermo Scientific, USA). Total RNA was extracted from snap-frozen surgical 170 specimens using Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA) as previously 171 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Technologies, Carlsbad, Ca) was reverse transcribed followed by amplification on an ABI 7500 196
Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad, CA). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
219
Comparison of miRNA expression between FVPTC and classic PTC. We identified twenty-220 one miRNAs significantly (p<0.05) deregulated (>2-fold up/down) in FVPTC as compared to 221 normal tissue with 14 of these deregulated more than 5-fold up or down (Table 2) . Strongly 222 upregulated miRNAs in FVPTC were miR-146b-3p, -146-5p, -221, -222 and miR-222-5p, -181a 223 which were previously reported in PTC (14, 17, 18) . Interestingly, the level of expression for 224 miR-146b-3p and miR-146b-5p was similar between FVPTC and classic PTC (30 to 33 fold for 225 miR-146b-3p and 73 to 77 fold for miR-146b-5p respectively); however, expression of miR-221 226 and miR-222-5p that are known to be upregulated in both PTC and FTC was twice higher in 227 FVPTC as compared to classic PTC. 228
229
We identified a number of downregulated miRNAs in both FVPTC and classic PTC including 230 miR-1179, -138, -144-5p, -199b-5p, -204, -219-5p and miR-451 (Table 2 ). The levels of 231 downregulation ranged between 3 and 54 fold. Four miRNAs were expressed significantly 232 differently in FVPTC compared to classic PTC with a fold change more than 5 (miR-125a-3p, -233 1271, -153, and -623) ( Table 2) . 234
235
In addition, two novel miRNAs miR-375 and miR-551b were found to be highly upregulated in 236 FVPTC. MiR-375 showed more than a 37-fold upregulation as compared to normal thyroid 237 tissue and miR-551b was upregulated more than 22-fold ( Table 2) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Validation of miR-375 expression. miR-375 was highly upregulated in FVPTC but at a lower 242 level in classic PTC using the array approach. To confirm array data and to determine whether 243 miR-375 upregulation is specific for papillary carcinoma, we studied its expression in an 244 independent set of 61 follicular cell derived neoplasms and normal thyroid tissue including 22 processes, including cell proliferation, differentiation, and cell death (10, 14). As a result, 277 miRNAs are directly involved in the development and progression of cancer representing an 278 important regulatory mechanism. In this study, we assess the miRNAome with the most 279 comprehensive currently available coverage of Sanger miRBase v.14 in a large series of FVPTC 280
samples. 281
There are several well characterized miRNAs known to be upregulated (miR-146b, -21, -221, -282 222) (14, 18, 19) and downregulated (miR-1, miR-138) (18, 20) in PTC. In the present work, we 283 have confirmed these findings, which underline the robustness of this analysis and also 284 strengthen the previously published work by ourselves and others. Interestingly, the level of 285 expression for miR-146b-3p and miR-146b-5p was similar between FVPTC and classic PTC; 286 however, expression of miR-221 and miR-222 that are known to be upregulated in both PTC and 287 FTC was twice higher in FVPTC as compared to classic PTC. Potentially, this may be due to the 288 fact that FVPTC share features of both classic PTC and FTC and miR-221 and miR-222 are 289 important in regulation of both tumor types. In addition, we previously demonstrated a 290 correlation between miRNA expression and the mutational status of PTC (14). We showed that 291 both miR-221 and miR-222 were stronger upregulated in PTC with RAS mutations, which are 292 commonly found in FVPTC. It would be potentially interesting to determine the prevalence of 293 RAS mutations in this cohort and correlate it with miRNA expression. 294
295
We identified several new, never before reported miRNAs being significantly upregulated in 296 FVPTC and classic PTC. MiR-375 was upregulated more than 35-fold in FVPTC and at 20-fold 297 in classic PTC and not found to be upregulated in normal thyroid tissue, hyperplastic nodules and 298 follicular carcinomas. High level and PTC-specific upregulation may indicate a potential 299 diagnostic utility for this miRNA. MiR-375 is known to play a role in other human malignancies 300 including lung and breast cancer (12, 21, 22) . Another miRNA found to be upregulated in both 301 tumor types was miR-551b. However, this miRNA has never been shown to play a role in any 302 human malignancy and therefore awaits confirmation in other studies and organ systems. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. with aggressive tumor behavior, although not all studies could confirm these findings (38). It is 325 evident that a subset of tumors harbouring the BRAF V600E mutation still has a good prognosis, 326 underscoring the need for new molecular markers. Recently, a correlation between deregulation 327 of miRNA expression in miR-146b, -222, and -130b and aggressiveness of PTC was reported 328 (20, 39) . In this study, we were able to confirm upregulation of miR-222 and also identified 329 novel markers of aggressiveness in FVPTC. Several miRNAs reached statistical significance 330 when looking into RFS including miR-181a-2-3p, -222, and -99b-3p. The Kaplan Meier survival 331 analysis was able to confirm a significant result for miR-181a-2-3p and miR-99b-3p. Patients 332 had an adverse outcome if miR-222 was expressed at a higher level and miR-181a-2-3p and 333 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
miR-99b-3p were expressed at a lower level and as compared to normal thyroid tissue. A 334 multivariate analysis including age, sex and tumor stage showed that the two latter miRNAs 335 were the only significant parameters, predicting patient relapse. MiR-181a-2-3p has not been 336 reported in human cancer before, but miR-99b-3p has been linked to prostate cancer (40, 41) . 337
Although further studies are needed to to confirm this finding in a larger cohort of patients, these 338 miRNAs bear the potential to serve as good molecular markers helping to stratify patients better 339 in the future and facilitate guiding appropriate clinical management. 340 341
In conclusion, we are reporting a comprehensive miRNA profile of FVPTC, the most common 342 histologic type of PTC. We discovered a new miRNA (miR-375) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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